Androgen receptor and prostate cancer: Molecular aspects and gene expression profiling

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 5, 2003, Pages 702-711

  Sommer, Anette ^a   Haendler, Bernard ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Androgen receptor; Expression profiling; Gene regulation; Post translational modification; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR;

AGING; ALLOSTERISM; CANCER GROWTH; CANCER RECURRENCE; DNA RESPONSIVE ELEMENT; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PROSTATE CANCER; PROTEIN PROCESSING; REVIEW; SURVIVAL;

ANDROGENS; ANIMALS; CARCINOMA; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 0142091422     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin (2002) 52(1):23-47.
2. Denmeade SR, Isaacs JT: A history of prostate cancer treatment. Nat Rev Cancer (2002) 2(5):389-396. A highly readable historical overview of the therapeutic options for treatment of prostate cancer.
3. Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G, Klocker H: Molecular biology of the androgen receptor: From molecular understanding to the clinic. Eur Urol (2001) 40(3):241-251.
4. Berrevoets CA, Umar A, Brinkmann AO: Antiandrogens: Selective androgen receptor modulators. Mol Cell Endocrinol (2002) 198(12):97-103.
5. Balk SP: Androgen receptor as a target in androgen-independent prostate cancer. Urology (2002) 60(3 Suppl 1):132-138.
6. Haendler B: Androgen-selective gene regulation in the prostate. Biomed Pharmacother (2002) 56(2):78-83.
7. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J et al: Androgen receptor mutations in prostate cancer. Cancer Res (2000) 60(4):944-949. A detailed survey of AR mutations in prostate cancer samples.
8. Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, Masters JR: Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol (2002) 198(2):237-244.
9. Moschos SJ, Mantzoros CS: The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology (2002) 63(4):317-332.
10. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET: Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev (2001) 12(1):33-40. An interesting review on the role of IL-6 in prostate cancer.
11. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC: HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res (2000) 60(24):6841-6845.
12. El Sheikh SS, Domin J, Abel P, Stamp G, Lalani EN: Androgen-independent prostate cancer: Potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia (2003) 5(2):99-109.
13. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ: Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res (2003) 63(8):1981-1989.
14. Lin HK, Yeh S, Kang HY, Chang C: Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA (2001) 98(13):7200-7205.
15. Craft N, Shostak Y, Carey M, Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med (1999) 5(3):280-285. A detailed study of the cross-talk between the AR and HER2/neu pathways.
16. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Cheng YT, Chang C: Interleukin-6 differentially regulates androgen receptor transactivation via P13K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun (2003) 305(3):462-469.
17. Ueda T, Bruchovsky N, Sadar MD: Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem (2002) 277(9):7076-7085.
18. Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W: AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol (2003) 23(1):104-118. Identification of a novel mechanism for prostate cancer cell survival that is independent of AR transcriptional function.
19. Hudes GR: Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs (2002) 20(2):159-173.
20. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF et al: Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem (2002) 277(32):29304-29314. A comprehensive analysis of AR phosphorylation sites and their functional relevance.
21. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C: Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J (2002) 21(15):4037-4048.
22. Beitel LK, Elhaji YA, Lumbroso R, Wing SS, Panet-Raymond V, Gottlieb B, Pinsky L, Trifiro MA: Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity. J Mol Endocrinol (2002) 29(1):41-60.
23. Smith CL, DeVera DG, Lamb DJ, Nawaz Z, Jiang YH, Beaudet AL, O'Malley BW: Genetic ablation of the steroid receptor coactivatorubiquitin ligase, E6-AP, results in tissue-selective steroid hormone resistance and defects in reproduction. Mol Cell Biol (2002) 22(2):525-535.
24. Gross M, Liu B, Tan JA, French FS, Carey M, Shuai K: Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene (2001) 20(29):3880-3887.
25. Kotaja N, Karvonen U, Jänne OA, Palvimo JJ: PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol (2002) 22(14):5222-5234. Extensive studies on the role of sumoylation in the regulation of transcriptional activity.
26. Nishida T, Yasuda H: PIAS1 and PIASxα function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J Biol Chem (2002) 277(44):41311-41317.
27. Tan JA, Hall SH, Hamil KG, Grossman G, Petrusz P, French FS: Protein inhibitors of activated STAT resemble scaffold attachment factors and function as interacting nuclear receptor coregulators. J Biol Chem (2002) 277(19):16993-17001.
28. Geserick C, Meyer HA, Barbulescu K, Haendler B: Differential modulation of androgen receptor action by DNA response elements. Mol Endocrinol (2003) 17(9):1738-1750. A detailed study of the role of response element sequences in regulating AR function.
29. Poukka H, Karvonen U, Jänne OA, Palvimo JJ: Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA (2000) 97(26):14145-14150. The first description of the importance of sumoylation in AR function.
30. Fan M, Long X, Bailey JA, Reed CA, Osborne E, Gize EA, Kirk EA, Bigsby RM, Nephew KP: The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol (2002) 16(2):315-330.
31. Fan M, Bigsby RM, Nephew KP: The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-α and essential for the antiproliferative activity of ICI 182,780 in ERα-positive breast cancer cells. Mol Endocrinol (2003) 17(3):356-365.
32. Meehan KL, Holland JW, Dawkins HJ: Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate (2002) 50(1):54-63.
33. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA, Jaffray E, Hay RT et al: Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol (2002) 22(10):3373-3388. A demonstration of the importance of acetylation for AR function.
34. Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN: Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene (2003) 22(16):2466-2477.
35. Thompson J, Saatcioglu F, Jänne OA, Palvimo JJ: Disrupted amino-and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol Endocrinol (2001) 15(6):923-935.
36. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM: Distinguishing androgen receptor agonists and antagonists: Distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol (1999) 13(3):440-454. A comparative study of the effects of androgens and anti-androgens on the N- and C-terminal interactions of the AR.
37. Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B: The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol (1999) 19(9):6085-6097.
38. He B, Bowen NT, Minges JT, Wilson EM: Androgen-induced NH2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem (2001) 276(45):42293-42301.
39. Li P, Yu X, Ge K, Melamed J, Roeder RG, Wang Z: Heterogenous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol (2002) 161(4):1467-1474.
40. Mestayer C, Blanchere M, Jaubert F, Dufour B, Mowszowicz I: Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines. Prostate (2003) 56(3):192-200.
41. Shang Y, Myers M, Brown M: Formation of the androgen receptor transcription complex. Mol Cell (2002) 9(3):601-610. An analysis of the AR transcription complex bound to the PSA promoter, detailing the different involvement of regulatory elements in activation and repression.
42. Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP: Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol (2002) 16(7):1492-1501.
43. Dotzlaw H, Moehren U, Mink S, Cato AC, Iñiguez Lluhi JA, Baniahmad A: The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol (2002) 16(4):661-673.
44. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, Basler S et al: Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem (2000) 275(34):26164-26171. The first publication of the crystal structure of the AR ligand binding domain in the presence of R1881.
45. Verrijdt G, Haelens A, Claessens F: Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genetics Metab (2003) 78(3):175-185. An overview on the importance of DNA response element sequences in mediating selective androgen response.
46. Barbulescu K, Geserick C, Schüttke I, Schleuning WD, Haendler B: New androgen response elements in the murine Pem promoter mediate selective transactivation. Mol Endocrinol (2001) 15(10):1803-1816.
47. Callewaert L, Verrijdt G, Christiaens V, Haelens A, Claessens F: Dual function of an amino-terminal amphipatic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements. J Biol Chem (2003) 278(10):8212-8218.
48. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B: The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA (2002) 99(18):11890-11895.
49. Schulze A, Downward J: Navigating gene expression using microarrays - a technology review. Nat Cell Biol (2001) 3(8):E190-E195.
50. Butte A: The use and analysis of microarray data. Nat Rev Drug Disc (2002) 1(12):951-960.
51. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO, Brooks JD: Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol (2002) 3(7):Research0032.1-Research0032.12. The most comprehensive study published to date on the response of several prostate cancer cell lines to various concentrations of different androgens (R1881, DHT) at multiple time points, with a biological interpretation of the interplay of the regulated genes.
52. Segawa T, Nau ME, Xu LL, Chilukuri RN, Makarem M, Zhang W, Petrovics G, Sesterhenn IA, McLeod DG, Moul JW, Vahey M et al: Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene (2002) 21(57):8749-8758.
53. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 412(6849):822-826. Gene expression profiling of various stages of prostate carcinoma was combined with tissue microarray analysis of two genes (hepsin and PIM1), followed by correlation with clinical outcome.
54. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr, Hampton GM: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res (2001) 61(16):5974-5978.
55. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 61(15):5692-5696.
56. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klären R, Gröne EF, Wiesel M, Güdemann C, Küster J et al: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma. A gene expression analysis on total and microdissected prostate tissue. Am J Pathol (2002) 160(6):2169-2180. Gene expression studies of prostate carcinoma samples were performed on microdissected epithelial and stromal healthy and cancerous prostate tissues, and revealed compartment-specific expression profiles.
57. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB: Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. Cancer Res (2001) 61(12):4683-4688.
58. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, Finkelstein S, Michalopoulos G, Becich M: Gene expression analysis of prostate cancers. Mol Carcinog (2002) 33(1):25-35. The analysis of matched pairs of prostate carcinoma and corresponding healthy tissue from the same patient identified a cluster of 12 genes that discrimate between metastatic and organ-confined prostate cancer.
59. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R, Zhang Z: Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol (2001) 166(6):2171-2177.
60. Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, Zhang Z, Warrington JA, Stamey TA: Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol (2003) 169(4):1316-1319.
61. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 419(6907):624-629. A functional study of EZH2, a transcription factor involved in tumor progression, which represses a specific group of genes.
62. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM: Meta yanalysis of microarrays: Interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 62(15):4427-4433. This paper describes the combined bioinformatic analysis of four gene expression studies from independent research groups using different array platforms. The purine and the polyamine biosynthesis pathways are identified to be dysregulated in prostate carcinoma.
63. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM: α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. J Am Med Assoc (2002) 287(13):1662-1670.
64. NCBI: Entrez Genome: National Center for Biotechnology Information, Bethesda, MD, USA. http://www.ncbi.nlm.nih.gov/entrez/queryfcgi?db=Genome
65. Genomenet: Kyoto University, Kyoto, Japan. http://www.genome.ad.jp/
66. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA: Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 95(9):661-668. A comparative study of the usefulness of 14 candidate biomarkers identified in expression profiling experiments as predictors for relapse following radical prostatectomy.
67. Rubin MA: Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer. J Pathol (2001) 195(1):80-86.
68. Asmann YW, Kosari F, Wang K, Cheville JC, Vasmatzis G: Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res (2002) 62(11):3308-3314.
69. Schwidetzky U, Haendler B, Schleuning WD: Isolation and characterization of the androgen-dependent mouse cysteine-rich secretory protein-3 (CRISP-3) gene. Biochem J (1995) 309(Pt 3):831-836.
70. Haendler B, Schüttke I, Schleuning WD: Androgen receptor signalling: Comparative analysis of androgen response elements and implication of heat-shock protein 90 and 14-3-3. Mol Cell Endocrinol (2001) 173(1-2):63-73.
71. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES et al: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 1(2):203-209. This paper contains the most extensive expression profiling study of prostate cancer and healthy prostate tissue starting from more than 100 human clinical samples. A five-gene model for prediction of patient outcome following prostatectomy is presented.
72. Berruti A, Dogliotti L, Mosca A, Gorzegno G, Bollito E, Mari M, Tarabuzzi R, Poggio M, Torta M, Fontana D, Angeli A: Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol (2001) 12(Suppl 2):153-157.
73. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res (2002) 62(15):4499-4506.
74. Vaarala MH, Porvari K, Kyllönen A, Vihko P: Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest (2000) 80(8):1259-1268.
75. Chakrabarti R, Robles LD, Gibson J, Muroski M: Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines. Cancer Genet Cytogenet (2002) 139(2):115-125.
76. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK: Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis (2002) 23(6):967-975.
77. Elek J, Park KH, Narayanan R: Microarray-based expression profiling in prostate tumors. In Vivo (2000) 14(1):173-182.
78. Bull JH, Ellison G, Patel A, Muir G, Walker M, Underwood M, Khan F, Paskins L: Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer (2001) 84(11):1512-1519.
79. Chaib H, Cockrell EK, Rubin MA, Macoska JA: Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia (2001) 3(1):43-52.
80. Chetcuti A, Margan S, Mann S, Russell P, Handelsman D, Rogers J, Dong Q: Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate (2001) 47(2):132-140.